Staff Writer Biotheranostics (San Diego), a specialist in the molecular diagnostics for cancer market, said it raised $32 million and will be spun out from Biomérieux SA (Marcy-l'Étoile, France). The financing was led by MVM Life Science Partners, with participation of Canepa Advanced Healthcare Fund and Healthquest Capital.

While stocks fell deep into the red across the board Wednesday, Glaukos Corp.'s (Laguana Hills, Calif.) share price (NYSE; GKOS) moved into the g reen by just a pinch after the company reported positive long-term data from an international study of its micro-bypass stent for glaucoma.